Eosinophilic granulomatosis with polyangiitis: Patient profiles from a large US allergy practice
The complex private practice presentation of EGPA, with heterogeneous patient response to standard treatments, highlights a significant disease burden and continued need for optimized treatment strategies within a multidisciplinary team approach.
Authors
- Mingchen Ye (ORCID: https://orcid.org/0009-0000-5915-5523)
- Lynn Huynh (ORCID: https://orcid.org/0000-0003-3110-6775)
- William McCann
- Michael E. Wechsler (ORCID: https://orcid.org/0000-0003-3505-2946)
- Anna Kovalszki (ORCID: https://orcid.org/0000-0002-1561-1977)
- Arijita Deb (ORCID: https://orcid.org/0000-0002-4570-0364)
- Mei Sheng Duh (ORCID: https://orcid.org/0000-0001-5035-6687)
- Jared Silver (ORCID: https://orcid.org/0000-0002-7838-0985)
- Brian Stone
- Anamika Khanal
Institutions
- University of Michigan (US)
- National Jewish Health (US)
- Analysis Group (United States) (US)
- University of Colorado Denver (US)
Publication Details
- Journal
- Journal of Allergy and Clinical Immunology Global
- Published
- 2025-02-04
- DOI
- https://doi.org/10.1016/j.jacig.2025.100437
- Citations
- 2
- Primary Topic
- Eosinophilic Disorders and Syndromes
- Type
- article
- Field-Weighted Citation Impact
- 3.34
Funders
- Amgen
- Eli Lilly and Company
- Pfizer
- AstraZeneca
- GlaxoSmithKline
- Sanofi
- Regeneron Pharmaceuticals
- Celldex Therapeutics
- Aimmune Therapeutics
- Incyte
- Apellis Pharmaceuticals
- Genentech
- National Heart, Lung, and Blood Institute
- National Institute of Allergy and Infectious Diseases